* Merck & Co Inc is expected to show a rise in quarterly revenue when it reports results on July 30 for the period ending June 30 2024
* The Rahway New Jersey-based company is expected to report a 5.4% increase in revenue to $15.841 billion from $15.04 billion a year ago, according to the mean estimate from 15 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Merck & Co Inc is for earnings of $2.15 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Merck & Co Inc is $145.00, above its last closing price of $125.85.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 1.83 1.88 2.07 Beat 10.4
Dec. 31 2024 -0.11 -0.11 0.03 Beat 127.5
Sep. 30 2023 1.98 1.95 2.13 Beat 9.2
Jun. 30 2023 -2.19 -2.18 -2.06 Beat 5.4
Jan. 1.31 1.32 1.40 Beat 5.9
1 0001
Dec. 31 2022 1.54 1.54 1.62 Beat 5.3
Sep. 30 2022 1.70 1.71 1.85 Beat 8.4
Jun. 30 2022 1.73 1.70 1.87 Beat 9.8
This summary was machine generated July 26 at 13:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments